###begin article-title 0
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
Deletion of Complement Factor H-Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome
###end article-title 0
###begin p 1
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFHR1)</italic>
###xml 446 454 446 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFHR3),</italic>
###xml 762 767 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 772 777 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 1235 1246 1223 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1/CFHR3</italic>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 1094 1102 <span type="species:ncbi:9606">patients</span>
###xml 1266 1274 <span type="species:ncbi:9606">patients</span>
Atypical hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. Disease-associated mutations have been described in the genes encoding the complement regulators complement factor H, membrane cofactor protein, factor B, and factor I. In this study, we show in two independent cohorts of aHUS patients that deletion of two closely related genes, complement factor H-related 1 (CFHR1) and complement factor H-related 3 (CFHR3), increases the risk of aHUS. Amplification analysis and sequencing of genomic DNA of three affected individuals revealed a chromosomal deletion of approximately84 kb in the RCA gene cluster, resulting in loss of the genes coding for CFHR1 and CFHR3, but leaving the genomic structure of factor H intact. The CFHR1 and CFHR3 genes are flanked by long homologous repeats with long interspersed nuclear elements (retrotransposons) and we suggest that nonallelic homologous recombination between these repeats results in the loss of the two genes. Impaired protection of erythrocytes from complement activation is observed in the serum of aHUS patients deficient in CFHR1 and CFHR3, thus suggesting a regulatory role for CFHR1 and CFHR3 in complement activation. The identification of CFHR1/CFHR3 deficiency in aHUS patients may lead to the design of new diagnostic approaches, such as enhanced testing for these genes.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 586 599 586 587 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8764;</bold>
###xml 800 805 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 810 816 798 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3,</italic>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
Hemolytic uremic syndrome (HUS) is a severe kidney disease, which is characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. The nondiarrhea-associated form, also known as atypical HUS (aHUS), is rare, sometimes familial, often recurrent, and has a poor outcome. Several studies have shown that aHUS is associated with mutations in genes coding for complement regulators, which leads to defective regulation of complement activation, particularly at cell surfaces. We report a novel susceptibility factor for aHUS in the form of a chromosomal deletion of a large (approximately84 kb) genomic fragment in the regulators of complement activation gene cluster at Chromosome 1q32. This deletion is a result of nonallelic homologous recombination and leads to the loss of two genes, CFHR1 and CFHR3, which encode factor H-related proteins 1 and 3, respectively. We recommend diagnostic screening of aHUS patients for these susceptibility factors.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b001">1</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b004">4</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b005">5</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b006">6</xref>
###xml 745 748 745 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 796 803 796 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFHR1)</italic>
###xml 805 806 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b007">7</xref>
###xml 949 950 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b008">8</xref>
###xml 953 956 953 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1026 1039 1026 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CFHR1&#8211;CFHR5)</italic>
###xml 1288 1291 1288 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1296 1307 1296 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1&#8211;CFHR5</italic>
###xml 1309 1310 1309 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b009">9</xref>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b010">10</xref>
###xml 1315 1316 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 1497 1499 1485 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b011">11</xref>
###xml 1613 1618 1601 1606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 1623 1629 1611 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3,</italic>
###xml 1641 1644 1629 1632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
Atypical hemolytic uremic syndrome (aHUS) is characterized by a triad consisting of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in the absence of a preceding diarrheal illness. aHUS can be either sporadic or familial. Defective complement regulation occurs in both sporadic and familial aHUS. Disease-associated mutations have been described for the genes encoding the complement regulators complement factor H (CFH), membrane cofactor protein, factor I, and factor B [1-4]. In addition, autoantibodies to factor H have been reported in aHUS patients [5]. Recently, we showed in a family with aHUS that nonallelic homologous recombination [6] results in the formation of a hybrid gene derived from exons 1-21 of CFH and exons 5-6 of complement factor H-related 1 (CFHR1) [7]. The protein product of this hybrid gene is identical to the aHUS-associated CFH mutant S1191L/V1197A, which arises through gene conversion [8]. CFH and the genes encoding the five complement factor H-related proteins (CFHR1-CFHR5) reside in a centromeric 355-kb segment on Chromosome 1. Sequence analysis of this region provides evidence for multiple independent large genomic duplications, also known as low-copy repeats, resulting in a high degree of sequence identity between CFH and CFHR1-CFHR5 [9, 10]. The secreted protein products of these genes are related in structure, as they are composed of repetitive units (approximately60 amino acids) named short consensus repeats (SCRs) [11]. In this study, we describe a novel form of nonallelic homologous recombination that results in the deletion of CFHR1 and CFHR3, but leaves CFH intact. This deletion is associated with an increased risk of aHUS.
###end p 6
###begin title 7
Results/Discussion
###end title 7
###begin p 8
###xml 275 283 275 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g001">Figure 1</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g001">1</xref>
###xml 490 491 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 500 501 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 707 710 705 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 847 850 845 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 854 859 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR4</italic>
###xml 861 869 859 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g002">Figure 2</xref>
###xml 1000 1005 998 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 1010 1015 1008 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 1045 1048 1043 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1065 1070 1063 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR4</italic>
###xml 1229 1232 1227 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1254 1259 1252 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 1294 1300 1292 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR-1</italic>
###xml 1495 1497 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b012">12</xref>
###xml 1841 1849 1827 1835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g002">Figure 2</xref>
###xml 2257 2265 2243 2251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g002">Figure 2</xref>
###xml 2353 2361 2339 2347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g002">Figure 2</xref>
###xml 2443 2451 2429 2437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g002">Figure 2</xref>
###xml 2603 2611 2589 2597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g003">Figure 3</xref>
###xml 2838 2846 2824 2832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g003">Figure 3</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 473 485 <span type="species:ncbi:9606">participants</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 922 930 <span type="species:ncbi:9606">patients</span>
###xml 1719 1727 <span type="species:ncbi:9606">patients</span>
###xml 2203 2210 <span type="species:ncbi:9606">patient</span>
###xml 2526 2533 <span type="species:ncbi:9606">patient</span>
###xml 2563 2570 <span type="species:ncbi:9606">patient</span>
###xml 2660 2668 <span type="species:ncbi:9606">patients</span>
###xml 2699 2707 <span type="species:ncbi:9606">patients</span>
Two cohorts of patients with aHUS have been studied, one from Jena, Germany and one from Newcastle, United Kingdom. For the Jena cohort of 121 aHUS patients, we used Western blotting to determine the absence of CFHR1 and CFHR3 in serum, as demonstrated for three patients in Figure 1A-1C. Complete absence of both CFHR1 and CFHR3 but presence of factor H, factor H-like protein 1, CFHR2, and CFHR4A was detected in 19 aHUS patients (16%) compared to two out of 100 control participants (chi2 = 10.4, p = 0.0012, odds ratio = 8.5). All 19 patients showed normal factor H serum levels. In three of these 19 patients, DNA analysis confirmed that the deficiency was caused by a homozygous genomic deletion. The CFH genes were normal, as determined by sequence analysis. Specific primers were designed which span the 113-kb region from the 3' exons of CFH to CFHR4 (Figure 2A). Failure of primers R2-R6 to amplify DNA of these patients is explained by a 84-kb deletion of a genomic fragment that includes CFHR3 and CFHR1 and is located downstream of CFH and upstream of CFHR4. This deletion is flanked by two duplicated segments, B and B', which are 28,638 bp and 28,714 bp in length, respectively. B includes exons 21, 22, and 23 of CFH and is located 5' of CFHR3. B' includes exons 3, 4, and 5 of CFHR-1 and is located approximately60 kb further downstream. Both segments have the same orientation, harbor several truncated long interspersed nuclear elements, and their sequence identity is >98 % [12]. The position of the deletion was mapped by amplifying regions of sequence variation between the duplicated segments. Forward and reverse primers specific for B and B', respectively, generated a 9.2-kb product from aHUS patients' DNA, but not from control DNA. Sequence analysis allowed the identification of nucleotides from either B or B' (Figure 2B), thus demonstrating fusion of B and B' as a result of nonallelic homologous recombination. This was confirmed by amplification of the fused segment BB' using primers that also generate amplification products from segment B and segment B' of control DNA. Sequence analysis of a divergent region in B and B' confirmed that amplification of DNA from the patient generated one product with a single sequence (Figure 2C, upper panel), while the control DNA generated two products with divergent sequences (Figure 2C, middle panel), of which one is derived from segment B and one from segment B' (Figure 2C, lower panel). These data demonstrate fusion of segments B and B' in the patient's DNA, and confirm that this patient is homozygous for the deletion (Figure 3A). The same results were obtained for the other patients (unpublished data). All three patients had identical breakpoints, which were mapped to a 1.9-kb region of perfect homology within or directly preceding a L1MA2 element (Figure 3B).
###end p 8
###begin p 9
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b013">13</xref>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 172 179 172 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030041-t001">Table 1</xref>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 351 352 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 361 362 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 373 375 371 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 426 431 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 609 610 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 619 620 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 631 633 627 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 660 665 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 767 768 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 777 778 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 692 700 <span type="species:ncbi:9606">patients</span>
The Newcastle cohort of 66 aHUS patients was investigated using multiplex ligation-dependent probe amplification (MLPA) [13] to measure copy number of CFHR1 exons 2 and 3 (Table 1). The data show that deletion of CFHR1 is strongly associated with aHUS. In the aHUS group, 28% of the patients had this deletion, compared to 6% of the control group (chi2 = 33.2, p = 1.0 x 10-8, odds ratio = 6.3). The following copy numbers of CFHR1 were found in aHUS patients: zero copies, 10%; one copy, 35%; two copies, 55%. In control subjects, the copy numbers were: zero copies, 2%; one copy, 9%; and two copies 89% (chi2 = 28.7, p = 5.9 x 10-7). The allele frequency of CFHR1 deletion was 30% in those patients known to carry a mutation and 27% in those without a mutation (chi2 = 0.16, p = 0.69).
###end p 9
###begin p 10
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b014">14</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b015">15</xref>
###xml 294 302 294 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-0030041-g004">Figure 4</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b016">16</xref>
###xml 170 175 <span type="species:ncbi:9940">sheep</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
The functional effect of complete deficiency of CFHR1 and CFHR3 proteins was investigated using a modified version of a hemolytic assay with factor H-depleted plasma and sheep erythrocytes [14, 15]. Addition of heat-inactivated serum from the three patients caused increased erythrocyte lysis (Figure 4). In contrast, serum derived from a healthy individual showed dose-dependent protection. These data show that CFHR1/CFHR3-deficient plasma has reduced protective activity and suggest that the absence of CFHR1 and/or CFHR3 contributes to the defective regulation of complement activation on cell and tissue surfaces. This is underlined by the fact that these patients have normal serum levels of factor H and factor I. Similarly, we previously showed that mutant factor H derived from HUS patients displayed reduced cell binding and protection activities [16].
###end p 10
###begin p 11
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 145 148 145 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b017">17</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b018">18</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b018">18</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
In this study we report that hetero- and homozygous deletion of CFHR1 and CFHR3 through nonallelic homologous recombination events downstream of CFH is associated with an increased risk of aHUS. aHUS patients with deficiency of CFHR1/CFHR3 are characterized by a relatively young age (1-21 y) at disease onset. Previously, we showed that deletion of CFHR1 and CFHR3 reduces the risk of age-related macular degeneration [17]. It is fascinating that the same polymorphic variant is associated with opposite effects: an increased risk for HUS and a decreased risk for age-related macular degeneration. How could this deletion be acting? One possibility is that the absence or presence of either CFHR1 and/or CFHR3 has a disease-modifying action. Although each of the two proteins alone lacks cofactor and decay-accelerating activity, CFHR3 has a cofactor-enhancing activity [18]. In addition, both CFHR1 and CFHR3 bind C3b and heparin, thus suggesting a regulatory function in C3b processing [18].
###end p 11
###begin p 12
###xml 107 110 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 133 136 133 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
Another possibility is that the deletion is in linkage disequilibrium with other susceptibility alleles in CFH or that it may affect CFH transcription. Understanding the functional effect of this disease-modifying deletion will help to extend our understanding of the role of complement in the pathogenesis of both aHUS and age-related macular degeneration.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants.
###end title 14
###begin p 15
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Newcastle.</italic>
###xml 152 155 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 298 301 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 354 363 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHR1</italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 461 466 <span type="species:ncbi:9606">human</span>
Newcastle. Sixty-six patients from Newcastle with a clinical diagnosis of aHUS were included in this study. Within this group, 15 were known to carry a CFH mutation, two carried a membrane cofactor protein mutation, and three carried a factor I mutation. Screening with MLPA for exons 22 and 23 of CFH showed that none of these patients carried a hybrid CFH/CFHR1 gene. The allele frequency of CFHR1 deletion in the aHUS patients was compared to 119 samples of human control DNA from a randomly selected population (healthy blood donors) obtained from the European Collection of Cell Cultures (). The study was approved by the Northern and Yorkshire Multi-Centre Research Ethics Committee.
###end p 15
###begin p 16
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Jena.</italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 210 217 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030041-t002">Table 2</xref>
###xml 266 275 266 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH/CFHR1</italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">Children</span>
Jena. A total of 121 aHUS patients from Jena were included in this study. Of these, 19 were found to be deficient in CFHR1 and CFHR3. Genomic deletion of CFHR1 and CFHR3 genes was determined in three patients (Table 2). None of these three patients carried a hybrid CFH/CFHR1 gene. The study was approved by the Research Ethics Committee of the University of Cologne, Germany, and by the Research Ethics Board of the Hospital for Sick Children, Toronto, Canada.
###end p 16
###begin title 17
Sera and Western blot analysis.
###end title 17
###begin p 18
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b019">19</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b020">20</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Serum samples from 121 aHUS patients (Jena cohort) and 100 anonymous healthy blood donors were assayed for the presence and mobility of factor H and CFHR1. Serum was separated by SDS-PAGE, transferred onto a membrane, and incubated with polyclonal factor H antiserum (Calbiochem-Novabiochem, ) or monoclonal C18 antibody [19], which identifies an epitope in factor H and CFHR1. CFHR3 was detected with polyclonal CFHR3 antiserum [20].
###end p 18
###begin title 19
Genetic analysis.
###end title 19
###begin p 20
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030041-t003">Table 3</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Genomic DNA was prepared from peripheral blood cells of three patients. Genomic DNA was amplified by PCR using specific primers R1-R8 that cover the 100-kb region downstream of the factor H gene (Table 3). Amplification of the breakpoint region and sequence analysis was performed using primers P9.2 and B1 and B2. For amplification of segment B and B', primer P was used. The sequence of the amplified products was determined using an ABI 3100 sequence analyzer (Applied Biosystems, www.appliedbiosystems.com). The sequences were compared to that of the genomic DNA of Chromosome 1. The sequences of segment B and segment B' were compared and analyzed for repeat content using CENSOR ().
###end p 20
###begin title 21
Erythrocyte lysis assay.
###end title 21
###begin p 22
###xml 516 517 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 696 697 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1331 1333 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b015">15</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 698 703 <span type="species:ncbi:9940">sheep</span>
###xml 877 882 <span type="species:ncbi:9606">human</span>
###xml 908 913 <span type="species:ncbi:9940">sheep</span>
###xml 1074 1079 <span type="species:ncbi:9606">human</span>
###xml 1124 1129 <span type="species:ncbi:9940">sheep</span>
###xml 1260 1265 <span type="species:ncbi:9606">human</span>
Factor H-depleted human plasma was prepared by immunoadsorbance of factor H from normal human plasma. Polyclonal factor H antiserum (Merck Biosciences, ) was covalently coupled to a 1-ml HiTrap NHS (N-hydroxy succimide) column (GE Health Care, ). Factor H depletion was confirmed by Western blotting, and ELISA showed that about 66% of the protein was removed. Depleted plasma was directly used for hemolytic assays. Hemolytic experiments were performed in VBS buffer (veronal buffered saline, 144 mM NaCl, 7 mM MgCl2, and 10 mM EGTA, pH 7.4). Increasing amounts of heat-inactivated (10 min at 56 degreesC) CFHR1/CFHR3-deficient serum or control serum were added to the depleted plasma and 2 x 107 sheep erythrocytes. Following incubation at 37 degreesC for 30 min, the mixture was cleared by centrifugation and the absorbance in the supernatants was measured at 414 nm. Using human complement active plasma sheep erythrocytes serve as non-activators of complement. These cells are protected from lysis and no hemoglobin is released. However, when factor H is depleted from human plasma, this plasma has the ability to lyse sheep erythrocytes, as demonstrated by the release of hemoglobin and an increase in absorbance. Addition of purified factor H or normal human heat-inactivated serum reconstitutes protection of erythrocytes [15].
###end p 22
###begin title 23
Multiplex ligation-dependent probe amplification.
###end title 23
###begin p 24
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen-0030041-b013">13</xref>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1,</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 433 440 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-0030041-t004">Table 4</xref>
The MLPA reaction has been previously described [13]. In this study, a completely synthetic probe set was used, obviating the need for a cloning step in the production of probes. Probes were designed to determine dosage for exons 2 and 3 of CFHR1, along with control probes for MSH2 exon 1 and MLH1 exon 19. Each probe pair hybridises to immediately adjacent targets at the sequence of interest. Hybridisation sequences are shown in Table 4. Probe pairs also contain binding sites for primers used in the MLPA reaction, as well as stuffer sequence to ensure that each amplified probe product is of a unique length. Oligonucleotides were obtained from TAG Newcastle, (). Righthand probes were 5'-phosphorylated and purified by desalting.
###end p 24
###begin p 25
###xml 649 650 646 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Reagents for the MLPA reaction were purchased from MRC-Holland (). The ligation reactions were carried out according to the manufacturer's recommended protocol using 100-200 ng of genomic DNA and 2 fmol of probe. Incubations and PCR amplification were carried out on a DNA Engine Tetrad 2 thermal cycler (). Amplified products were diluted 10-fold to give peak heights within the quantitative range (approximately 100-4,000 units) on the ABI PRISM 3130 Genetic Analyzer capillary electrophoresis system (Applied Biosystems, ). Diluted product (1 mul) and 0.5 mul of ROX 500 internal size standard (Applied Biosystems) were made up to 10 mul using dH2O and samples were run on the ABI 3130. Peak areas for each sample were determined using the proprietary Genemapper software (Applied Biosystems) and dosage quotients calculated.
###end p 25
###begin title 26
Supporting Information
###end title 26
###begin title 27
Accession Numbers
###end title 27
###begin p 28
###xml 123 135 123 135 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Homo sapiens</named-content>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 123 135 <span type="species:ncbi:9606">Homo sapiens</span>
The National Center for Biotechnology Information (NCBI) () accession number for the sequences discussed in this paper are Homo sapiens Chromosome 1 genomic DNA (NT_004487.18/Hs1_4644), MLH1 (NM_000249), and MSH2 (NM_000251).
###end p 28
###begin p 29
###xml 13 21 <span type="species:ncbi:9606">patients</span>
We thank the patients and physicians who participated in this study. Five probes in the Jena cohort were conceived from the HUS registry collected by the Arbeitskreis Padiatrische Nephrologie in Germany. We thank Gerlinde Heckrodt and Ina Loschmann for their expert technical assistance.
###end p 29
###begin title 30
Abbreviations
###end title 30
###begin p 31
atypical hemolytic uremic syndrome
###end p 31
###begin p 32
complement factor H
###end p 32
###begin p 33
complement factor H-related
###end p 33
###begin p 34
hemolytic uremic syndrome
###end p 34
###begin p 35
multiplex ligation-dependent probe amplification
###end p 35
###begin p 36
short consensus repeats
###end p 36
###begin title 37
References
###end title 37
###begin article-title 38
Complement dysfunction in hemolytic uremic syndrome
###end article-title 38
###begin article-title 39
Atypical haemolytic uraemic syndrome
###end article-title 39
###begin article-title 40
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease
###end article-title 40
###begin article-title 41
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome
###end article-title 41
###begin article-title 42
Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome
###end article-title 42
###begin article-title 43
Genomic disorders: Molecular mechanisms for rearrangements and conveyed phenotypes
###end article-title 43
###begin article-title 44
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene
###end article-title 44
###begin article-title 45
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome
###end article-title 45
###begin article-title 46
A radiation hybrid map of complement factor H and factor H-related genes
###end article-title 46
###begin article-title 47
The factor H protein family
###end article-title 47
###begin article-title 48
Complement factor H and related proteins: An expanding family of complement-regulatory proteins?
###end article-title 48
###begin article-title 49
###xml 52 57 <span type="species:ncbi:9606">human</span>
Complement factor H: Sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes
###end article-title 49
###begin article-title 50
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
###end article-title 50
###begin article-title 51
Cutting edge: Localization of the host recognition functions of complement factor H at the carboxyl-terminal: Implications for hemolytic uremic syndrome
###end article-title 51
###begin article-title 52
Hemolytic Uremic Syndrome: A factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells
###end article-title 52
###begin article-title 53
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome
###end article-title 53
###begin article-title 54
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration
###end article-title 54
###begin article-title 55
Functional properties of complement factor H-related proteins FHR-3 and FHR-4: Binding to the C3d region of C3b and differential regulation by heparin
###end article-title 55
###begin article-title 56
The C-terminus of complement regulator Factor H mediates target recognition: Evidence for a compact conformation of the native protein
###end article-title 56
###begin article-title 57
###xml 65 70 <span type="species:ncbi:9606">human</span>
A novel short consensus repeat-containing molecule is related to human complement factor H
###end article-title 57
###begin title 58
Figures and Tables
###end title 58
###begin title 59
Deficiency of CFHR1 and CFHR3 in HUS
###end title 59
###begin p 60
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Western blotting of serum from three HUS patients (lanes 1-3) and a control subject (lane 4).
###end p 60
###begin p 61
###xml 129 137 <span type="species:ncbi:9606">patients</span>
 (A) Using a monoclonal antibody that reacts with the C terminus of CFHR1, complete deficiency of CFHR1 is seen in the three HUS patients. The normal control shows the two differently glycosylated forms of CFHR1 (CFHR1alpha and CFHR1beta, respectively).
###end p 61
###begin p 62
###xml 77 85 <span type="species:ncbi:9606">patients</span>
(B) Using CFHR3 antiserum, complete deficiency of CFHR3 is seen in three HUS patients, but CFHR3 is detected in the control subject. CFHR4A is present in all samples.
###end p 62
###begin p 63
###xml 30 38 <span type="species:ncbi:9606">patients</span>
(C) The sera of the three HUS patients contain factor H-like protein 1 and the glycosylated and nonglycosylated forms of CFHR2 (CFHR2alpha and CFHR2, respectively).
###end p 63
###begin title 64
###xml 11 16 <span type="species:ncbi:9606">Human</span>
Map of the Human Factor H Gene Cluster
###end title 64
###begin p 65
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1,</italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR4</italic>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
(A) The 20 SCRs of CFH, the five SCRs of CFHR3, the fiveSCRs of CFHR1, and the nine SCRs of CFHR4 are indicated by vertical bars. The position of the two duplicated homologous segments (B and B') and that of the eight primer pairs (R1-R8) is shown. Failure (-) to amplify DNA downstream of CFH in the three HUS patients reveals a deletion of a genomic approximately84-kb fragment.
###end p 65
###begin p 66
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
(B) Sequence comparison of segment B (red) and segment B' (yellow) reveals blocks with sequence diversity. Fusion of the homologous segments and localization of the breakpoints in three CFHR1/CFHR3 deficient HUS patients are indicated. Fusion of segments B and B' is demonstrated by amplification of a 9.2-kb PCR fragment using a forward primer specific for segment B and a reverse primer specific for segment B'. For all three patients, sequences of block 1 are derived from segment B (red) and sequences of block 2 are derived from segment B' (yellow).
###end p 66
###begin p 67
###xml 190 197 <span type="species:ncbi:9606">patient</span>
###xml 294 300 <span type="species:ncbi:9606">person</span>
###xml 395 401 <span type="species:ncbi:9606">person</span>
(C) Similar PCR products were generated with primers common for segment B and segment B'. Amplification of both segments is confirmed by sequence analysis. Sequence of PCR products from the patient is identical to segment B of a control DNA (upper panel). Sequence of PCR products of a control person is identical to segment B and B' (middle panel). Identification of sequence B' of the control person (lower panel). Sequence differences between segment B and segment B' are indicated (grey bar).
###end p 67
###begin title 68
Chromosomal Rearrangement of Segments B and B'
###end title 68
###begin p 69
(A) Homologous recombination between segments B and B' in the RCA gene cluster results in deletion of the genes coding for CFHR1 and CFHR3 and fusion of segments B and B' as described in the text.
###end p 69
###begin p 70
###xml 229 237 <span type="species:ncbi:9606">patients</span>
(B) The B and B' segments in the factor H gene cluster are characterized by high sequence identity (98%) and include several truncated long interspersed nuclear elements (retrotransposons). The breakpoint identified in all three patients is indicated by the arrow.
###end p 70
###begin title 71
Defective Protective Activity with CFHR1/CFHR3 Deficient Plasma
###end title 71
###begin p 72
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 109 114 <span type="species:ncbi:9940">Sheep</span>
###xml 166 171 <span type="species:ncbi:9606">human</span>
###xml 180 185 <span type="species:ncbi:9940">Sheep</span>
###xml 247 252 <span type="species:ncbi:9606">human</span>
###xml 321 326 <span type="species:ncbi:9940">sheep</span>
###xml 535 540 <span type="species:ncbi:9606">human</span>
###xml 556 563 <span type="species:ncbi:9606">patient</span>
A novel type of hemolytic assay was used to analyze hemolytic activity of CFHR1/CFHR3 deficient human serum. Sheep erythrocytes were incubated with factor H-depleted human plasma. Sheep erythrocytes generally act as nonactivators of complement in human plasma. However, depletion of factor H from the plasma converts the sheep erythrocytes into activator surfaces (ctrl, empty circle). Addition of heat inactivated serum to depleted plasma as a source of factor H has a dose-dependent protective effect ("control"). Compared to normal human serum, sera of patient P1 to P3 with CFHR1/CFHR3 deficiency showed less protective activity as indicated by the increased lysis of erythrocytes. The classical pathway of complement activation was inhibited by the chelating agent EGTA. Erythrocytes incubated in buffer do not lyse (ctrl, filled circle). Mean values and standard deviations of three separate experiments are shown.
###end p 72
###begin p 73
Ctrl, control
###end p 73
###begin p 74
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 75 83 <span type="species:ncbi:9606">Patients</span>
Frequency of CFHR1 Deletion and Copy Number of CFHR1 Exons 2 and 3 in aHUS Patients and Controls (Newcastle Cohort)
###end p 74
###begin p 75
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 17 25 <span type="species:ncbi:9606">Patients</span>
Profile of Three Patients Deficient in CFHR1 and CFHR3
###end p 75
###begin p 76
Primer Sequences for PCR Amplification and Sequencing
###end p 76
###begin p 77
MLPA Primers
###end p 77
###begin p 78
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 78
###begin p 79
A previous version of this article appeared as an Early Online Release on February 1, 2007 (doi:).
###end p 79
###begin p 80
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
Author contributions. ME, SH, MJ, HR, DR, LS, and AEH performed the experiments. PFZ, JAG, THJG, and CS conceived and designed the experiments and analyzed the data. JM, BH, CL, and THJG took care of the patients, contributed material, and discussed data. PFZ, THJG, and CS wrote the paper.
###end p 80
###begin p 81
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
###xml 130 138 <span type="species:ncbi:9606">Children</span>
Funding. This work was supported by the Deutsche Forschungs Gemeinschaft (DFG, PZ 432), the Robin Davis Trust, the Foundation for Children with atypical HUS, and KIDNEEDS.
###end p 81

